Search

HAPLO-iPS • COST ACTION CA21151

WG3 • Quality control, Biobanking and Registration of cell lines

Quality control in hiPSC lines banking and Registry of hiPSC

Working group 3 shall identify optimal systems for safety-assured and reliable cell therapies to promote standardization of hiPSC scaling and banking for basic and clinical researchers and regulators. Based on the existing European human Pluripotent Stem Cell Registry (hPSCreg), the team of experts shall define the hiPSC-associated data to be collected and develop a data resource, access platform and registry for available hiPSC lines suitable for the manufacture of therapeutic products.

Objectives

WG3 Leaders

CG-_0018_Andreas Kurtz
Andreas Kurtz
WG3 Leader
Fraunhofer Institute for Biomedical Engineering
andreas.kurtz@ibmt.fraunhofer.de
Germany
Germany
CG-_0011_Dawid Grzela
Dawid Grzela
WG3 Co-leader
Polish Academy of Sciences
dgrzela@cbm.pan.pl
Poland
Poland

Description of Work

T3.1

Literature review on quality control for hiPSC for the manufacture cell therapy products and meeting with product developers and regulators to identify recommended standards to be used for hiPSC production and biobanking.

T3.2

Workshop to review Task 3.1 output and agree quality, safety and standards guideline document including scientific, technological and regulatory challenges for Biobanking.

T3.3

Registry implementation: literature review on international management of data, data standards and output involving data experts and map optimal route for stem data interoperability and registration. Incorporation into the hPSCreg.

Deliverables and milestones

D3.1

Guidelines and standards road-map document and quality manual for hiPSC biobanking.

D3.2

Report of database for inclusion into European human Pluripotent Stem Cell Registry (hPSCreg).

M3.1

Establish standards required for production and biobanking of hiPSC for the manufacture of products for cell therapy.

M3.2

Selection of hiPSC line data to be collected.

WG3 Participants

Adel Meguireche
Working Group: WG1, WG2, WG3, WG4, WG5, WG6, WG7
University badji Mokhtar Annaba Algeria
Algeria
Algeria
Ayten Kandilci
Working Group: WG1, WG2, WG3, WG6
Gebze Technical University
Turkey
Turkey
Aleksandar Petlichkovski
Working Group: WG1, WG3, WG6
Faculty of Medicine
North Macedonia
North Macedonia
Alvaro Plaza Reyes
Working Group: WG2, WG3, WG6, WG7
Fundación Pública Andaluza, Progreso y Salud
Spain
Spain
Andreas Kurtz
Working Group: WG3, WG5, WG6
Fraunhofer Institute for Biomedical Engineering
Germany
Germany
Anna Falk
Working Group: WG2, WG3
Lund University
Sweden
Sweden
Annelise Bennaceur Griscelli
Working Group: WG1, WG2, WG3, WG7
University Paris Saclay
France
France
Emiran Defne Atay
Working Group: WG1, WG2, WG3, WG4, WG5, WG6, WG7
Acibadem Mehmet Ali Aydinlar University
Turkey
Turkey
Begoña Aran
Working Group: WG2, WG3, WG7
Institut d'Investigació Biomèdica de Bellvitge
Spain
Spain
Benjamin Kurtze
Working Group: WG2, WG3, WG7
Freie Universitaet Berlin
Germany
Germany
Berivan Töre
Working Group: WG2, WG3
Hacettepe Universitesi
Turkey
Turkey
Belen Prados Pinto
Working Group: WG2, WG3, WG7
Centro Nacional de Investigaciones Cardiovasculares
Spain
Spain
Loading more